key: cord-0982238-td62tfcb authors: Perera, Pin-Yu; Perera, Liyanage P. title: Development of leading first-generation vaccines against SARS-CoV-2 date: 2021-05-20 journal: Microbes Infect DOI: 10.1016/j.micinf.2021.104841 sha: f86f4a161fc5ca2b64e1b53cb26e315e80a3cd38 doc_id: 982238 cord_uid: td62tfcb SARS-CoV-2 has infected more than 152 million individuals globally. Highly effective and safe vaccines are required to accelerate the development of herd immunity to end the pandemic. This review focuses on vaccines that are being developed at unprecedented speed globally and are completing late phase clinical trials to meet this urgent need. exceptional circumstances for use in a prime-boost vaccine regimen against Ebola [34] . The Ad26ZEBOV is the first non-replicating human adenovirus-26 vectored vaccine to be approved 187 for human use [34] . responses without adjuvants, adjuvants are added to enhance specific immune responses [36] . The manufacturing process is well established for protein subunit and virus like particle vaccines 199 and several of these vaccines have been commercially produced and licensed for human use Nucleic acid vaccines, both in vitro transcribed messenger RNA (mRNA) and plasmid-204 based DNA vaccines are much faster to produce than other types of vaccines described once the 205 genetic sequence of the target antigen is known [37] . RNA vaccines rely on the cells that receive . An ideal animal model to test SARS-CoV-2 vaccines has not been identified 223 due to the inability of current animal models to fully recapitulate human disease [42] . However, 224 different animals including mice, rats, ferrets, hamsters, cats, and nonhuman primates provide 225 reasonable models of different aspects of the spectrum of human Covid-19 disease [42] . SARS- CoV-2 infected human ACE2 transgenic mice are useful for vaccine immunogenicity and live 227 virus challenge studies [42] . Infected Syrian golden hamsters develop severe disease with rapid 228 weight loss and severe lung pathology and model severe human disease [43] . Ferrets, golden 229 hamsters, and cats are useful to study air-borne transmission of the virus [42, 43] . Outbred concentrations of binding antibodies with poor neutralizing ability, a concern that has received 236 much scrutiny [45] . In support of this concern, when post-vaccinated animals are subsequently 237 challenged with live viruses these suboptimal antibodies can induce an enhanced uptake of 238 antibody-bound viruses into susceptible cells through Fc receptors or complement receptors with 239 worsening disease [45] . This immune enhancement of disease was seen in mice challenged with 240 SARS-CoV-1 and MERS-CoV viruses, after inoculation with vaccines that induced a T helper 241 cell type 2 biased immune response with eosinophilic pulmonary infiltrates [45] . As a safety 242 measure all current Covid-19 candidate vaccines are required to be tested for vaccine-induced hundreds of patients and are in phase 3 trials for efficacy, that will involve several thousands of 252 volunteer participants [50] [51] [52] [53] [54] [55] . It is anticipated that at least 30,000 volunteer participants will be 253 tested in phase 3 trials before a vaccine is licensed. Table 2 qualifying symptoms for Covid-19 case determination as described in Table 3 . It should be noted 264 that the qualifying symptoms used to classify disease as "mild". "moderate", "severe" or "very 265 severe/critical/hospitalized" vary between trials. Efficacy will be determined by calculating the 266 illness rate in the vaccine group to the corresponding illness rate in the placebo group as pre-267 specified in each clinical protocol or as described in the phase 3 trial [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] . Symptomatic alternatives are available, with data to support that the vaccine "may be effective" and the likely 277 benefits outweigh the harms [61] . In the updated October 2020 EUA guidance, the FDA further recommended the inclusion of data from a median follow-up of two months after the last dose of 279 the vaccine for trial participants, as added safety and effectiveness measures to ensure that the 280 vaccine induced protection is due to adaptive and memory immune responses and not early 281 innate immune responses [61] . Additionally, the placebo group should include data from 5 or 282 more severe Covid-19 infected participants to support low risk for vaccine-induced enhanced 283 respiratory disease [61] . Based on first interim analysis of early phase 3 trial data as specified in 284 each vaccine clinical trial protocol, manufacturers may seek EUA for their vaccines [50] [51] [52] [53] . Once all trial data and manufacturing information are submitted to the FDA by the manufacturer 286 with a request for EUA, FDA will convene the Vaccines and Related Biological Products 287 Advisory Committee (VRBPAC) made up of outside scientific and public health experts to 288 discuss the safety and effectiveness of the submitted data [61] . This committee will advise FDA 289 on their evaluations and FDA will then decide whether to authorize a vaccine for emergency use 290 for the prevention of Covid-19 based on the totality of submitted data [61] . Despite the FDA 291 recommendation that trials continue after EUA for as long as it is feasible, an EUA can lead to 292 risks for manufacturers if the study is unblinded to allow participants in the placebo group to Results from the efficacy analyses of 6 leading Covid-19 candidate vaccines in ongoing 299 phase 3 randomized, controlled trials are summarized in Table 4 . Some important factors need to systemic reactions: headache, fatigue, muscle pain) associated with immunization, no serious 320 safety concerns were identified easing the concern over potential vaccine-mediated disease 321 enhancement, during the short duration of these two trials [57, 58] . Furthermore, trial participants 322 will be followed for two years for immunogenicity, longer-term safety and efficacy assessments virus spike protein, as more variants of concern develop and may require additional booster 396 doses targeting these newer variants [69] . There is an added concern that the reported rapid Importantly, clinical trials for the vaccines that were evaluated were not powered to 431 directly test whether these vaccines will prevent severe disease, instead these trials were 432 designed to test whether the vaccine will protect against development of milder disease with RT- According to the most recent United Nations estimates, the world population is 7.8 550 billion as of January 2020, populating 195 countries. Several effective and safe vaccines will be 551 required to induce herd immunity in the global population, including vaccines specifically 552 targeted to the very young, elderly, pregnant and lactating women, women of child-bearing age 553 and the immune compromised. To stop a pandemic, a global vaccination campaign will require multilateral cooperation between governments, regulatory authorities and equitable worldwide 555 distribution of vaccines. How we meet these challenges in the coming years will foretell whether 556 the SARS-CoV-2 virus can be effectively controlled or will remain as an endemic virus 557 constantly evolving and giving rise to periodic and devastating outbreaks. The primary endpoint for the Ad26COV2S vaccine is prevention of moderate to severe/critical Covid-19 disease. For Gamaleya Sputnik V extremely severe course includes multiorgan failure and changes in the lungs on CT(X-ray) or an evidence of adult respiratory distress syndrome. FiO2, fraction of inspired oxygen; PaO2, partial pressure of oxygen, arterial; SpO2, oxygen saturation as measured by pulse oximetry. J o u r n a l P r e -p r o o f Geographic differences in COVID-19 cases, deaths, and 600 incidence -United States Covid-19: four fifths of cases are asymptomatic, China figures indicate Apr 2 Herd immunity and implications for SARS-CoV-2 605 control Prevalence of asymptomatic SARS-CoV-2 infection: A narrative 607 review Presymptomatic transmission of 609 SARS-CoV-2 -Singapore Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1 COVID-19 infection: Origin, 615 transmission, and characteristics of human coronaviruses Origin and evolution of pathogenic coronaviruses Genomic characterization of the 619 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia 620 after visiting Wuhan Cell entry mechanisms of 632 SARS-CoV-2 Convergent 634 antibody responses to SARS-CoV-2 in convalescent individuals SARS-CoV-2 637 entry factors are highly expressed in nasal epithelial cells together with innate immune 638 genes Acute SARS-CoV-2 infection 640 impairs dendritic cell and T cell responses Mild or moderate Covid-19 Impaired type I 644 interferon activity and inflammatory responses in severe COVID-19 patients Virology, transmission, and pathogenesis of 647 SARS-CoV-2 WHO draft landscape of COVID-19 candidate vaccines Accessed 29 Why are vaccines against many human viral diseases still 652 unavailable; an historic perspective Inactivated virus vaccines from chemistry 654 to prophylaxis: merits, risks and challenges Vaccine adjuvants: putting innate immunity to work T-cell-inducing vaccines-what's the future A highly 659 immunogenic and protective middle east respiratory syndrome coronavirus vaccine based 660 on a recombinant measles virus vaccine platform The vesicular stomatitis virus-662 based Ebola virus vaccine: From concept to clinical trials Adenoviruses as vaccine vectors Safety and 666 immunogenicity of a 2-dose Ebola vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo 667 in a Phase III Recombinant protein vaccines produced in insect cells Virus-like particle vaccines: 674 immunology and formulation for clinical translation The promise of nucleic acid vaccines Amplifying RNA vaccine development mRNA vaccine 681 delivery using lipid nanoparticles Advancements in DNA vaccine vectors, non-683 mechanical delivery methods, and molecular adjuvants to increase immunogenicity Animal models for highly pathogenic emerging 686 viruses The search for a COVID-19 animal model Pathogenesis and 690 transmission of SARS-CoV-2 in golden hamsters CoV-2 infection protects against rechallenge in rhesus macaques Consensus summary report for CEPI/BC 695 March 12-13, 2020 meeting: Assessment of risk of disease enhancement with Covid-19 696 vaccines Safety, tolerability, and 698 immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-699 escalation, open-label, non-randomised, first-in-human trial Safety and immunogenicity of 702 an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-703 controlled, phase 1/2 trial Safety and 705 immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, 706 randomised, phase 1 trial CoV-2 recombinant spike protein nanoparticle vaccine Updated protocol. A phase 1/2/3, placebo-controlled, randomized, observer-blind, 711 dose finding study to evaluate the safety, tolerability SARS-CoV-2 RNA vaccine candidates against Covid-19 in healthy individuals Clinical trial protocol. A phase 3, randomized, stratified, observer-blind, 716 placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of mRNA SARS-CoV-2 vaccine in adults aged 18 years and older Janssen Vaccines & Prevention B.V. Clinical protocol. A randomized, double-blind, 721 placebo-controlled phase 3 study to assess the efficacy and safety of Ad26.COV2.S for the 722 prevention of SARS-CoV-2-mediated COVID-19 in adults aged 18 years and older Phase III randomized, double-blind, placebo-726 controlled multicenter study in adults to determine the safety, efficacy, and 727 immunogenicity of AZD1222, a non-replicating ChAdOx1 vector vaccine, for the 728 prevention of COVID-19 /D8110C00001/52bec400-80f6-4c1b-8791-0483923d0867/c8070a4e-6a9d-46f9-8c32-730 cece903592b9/D8110C00001_CSP-v2 Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the (inactivated) vaccine manufactured by Sinovac -PROFISCOV: A structured summary of a 735 study protocol for a randomised controlled trial Safety and efficacy of an rAd26 and rAd5 vector-based 738 heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised 739 controlled phase 3 trial in Russia Single-dose administration and the influence of the timing of the booster dose on 742 immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled 743 analysis of four randomised trials Safety and 745 efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety 748 of the mRNA-1273 SARS-CoV-2 vaccine Safety and 750 efficacy of single-dose Ad26.COV2.S vaccine against Covid-19 US Food and Drug Administration. Development and licensure of vaccines to prevent 753 COVID-19 guidance for industry Emergency use authorization for vaccines to prevent 756 COVID-19 guidance for industry Safety and 759 efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim 760 analysis of four randomised controlled trials in Brazil, South Africa, and the UK COVID-19 and 763 the elderly: insights into pathogenesis and clinical decision-making COVID-19 766 disparity among racial and ethnic minorities in the US: A cross sectional analysis Tracking 769 changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-770 19 virus 30 th WHO regulatory update on COVID-19 Covid-19: What new variants are emerging and how are they being 774 investigated? Neutralizing activity 776 of BNT162b2-elicited serum ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant Case 781 Study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic 782 immunocompromised individual with cancer SARS-CoV-2 spillover events COVID-19 vaccine 785 response in pregnant and lactating women: a cohort study COVID vaccines and kids: five questions as trials begin Will covid-19 vaccines save lives? Current trials aren't designed to tell us mRNA 792 vaccines to prevent COVID-19 disease and reported allergic reactions: Current evidence 793 and suggested approach COVID vaccines and blood clots: five key questions FDA news release. FDA and CDC lift recommended pause on Johnson & Johnson 797 COVID-19 vaccine use following through safety review A global survey 802 of potential acceptance of a COVID-19 vaccine COVID-19 human challenge studies: ethical issues Dozens to be deliberately infected with coronavirus in UK human challenge 806 trials Remdesivir 808 for the Treatment of Covid-19 -Final Report Baricitinib plus remdesivir for hospitalized adults with Covid-19 Effect of 813 dexamethasone on days alive and ventilator-free in patients with moderate or severe acute 814 respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial Accessed 29 J o u r n a l P r e -p r o o f